Evaluation of the effectiveness of interferon use in children with frequent recurrent respiratory diseases

Objective. To evaluate the therapeutic and prophylactic efficacy of recombinant interferon in children with recurrent diseases using quality of life (QOL) indicators. Materials and methods. An assessment of the possibilities of using QOL indicators to analyze the effectiveness of preventive and therapeutic measures carried out in 126 frequently and long-term ill children aged 1 to 6 years with recurrent respiratory infections living in Dushanbe. Results. The results of the examination of 126 children with recurrent respiratory infections indicate a favorable outcome of the disease with properly selected therapy using recombinant interferon-alpha- 2b with antioxidants (Viferon®) in noninvasive dosage forms. Early administration of the drug significantly reduced the duration of fever with a tendency to reduce catarrhal symptoms. The drug was used as part of complex therapy at a dosage of 150,000 IU per 1 suppository rectally 2 times a day for 5 days. The positive dynamics in the general somatic status of frequently and long-term ill children contributed to an increase in the parameters of their quality of life, especially such aspects as emotional and social well-being. Conclusion. The convenient dosage form, high therapeutic and prophylactic efficacy of Viferon®a, and the focus on the immune system make it possible to recommend this drug in the complex treatment and prevention of children with recurrent respiratory infections.